NCT02035813View on ClinicalTrials.gov

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

PHASE2CompletedINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions

HER2-negative and Hormone-receptor Positive Metastatic Breast CancerHER2-negative Circulating Tumor CellsPostmenopausal Female Patients

Interventions

DRUG

Ribociclib

Ribociclib/Everolimus in combination with endocrine therapy

DRUG

Eribulin

Trial Locations (1)

89075

University Hospital Ulm -Department of Gynecology, Ulm

All Listed Sponsors

lead

Prof. Wolfgang Janni

OTHER

NCT02035813 - DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). | Biotech Hunter | Biotech Hunter